Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.44 |
| ▸ | NMT2 | O60551 | 6/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23604792 | 0.83 | NMT1 (0.45) | NMT1NMT2SLC6A5FOLH1SIRT6 | |
| SCHEMBL19362990 | 0.79 | CPB2 (0.40) | NMT1NMT2SLC6A5FOLH1SIRT6 | |
| SCHEMBL13995535 | 0.76 | SIRT6 (0.52) | FOLH1SIRT6SIRT1TLR2CPB2 | |
| SCHEMBL21566733 | 0.76 | SIRT6 (0.52) | FOLH1SIRT6SIRT1TLR2CPB2 | |
| SCHEMBL19200235 | 0.76 | SIRT6 (0.52) | FOLH1SIRT6SIRT1TLR2CPB2 | |
| SCHEMBL7034267 | 0.76 | SLC6A5 (0.62) | NMT1NMT2SLC6A5FOLH1CPB2 | |
| SCHEMBL7034266 | 0.76 | SLC6A5 (0.62) | NMT1NMT2SLC6A5FOLH1CPB2 | |
| SCHEMBL20682458 | 0.76 | SIRT6 (0.40) | FOLH1SIRT6SIRT1ITGB3ITGA2B | |
| SCHEMBL29299856 | 0.75 | NMT1 (0.58) | NMT1NMT2SIRT6SIRT1TLR2 | |
| SCHEMBL21566738 | 0.75 | SIRT6 (0.55) | SLC6A5FOLH1SIRT6SIRT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | NMT1 664/4885NMT2 688/4885SLC6A5 2671/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | NMT1 664/4885NMT2 688/4885SLC6A5 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.